“…[54][55][56][57] The most relevant examples are: i) the 4-(phenylethynyl)benzamide derivatives LPC-004 and CHIR-090, [58,59] the 4-(phenylbuta-1,3-diyn-1-yl)benzamide derivatives LPC-009 and LPC-011, [60] all of which were developed by Chiron and the University of Washington; ii) the difluoromethyl derivative LPC-058 developed by C. -J. Lee et al; [61] iii) the pyridine methylsulfone LpxC-4 (PF-5081090), [62,63] which was discovered by Pfizer; and iv) the cyclopropane derivative ACHN-975 [56] developed by Achaogen (Figure 5). Diverse crystal structures of the LpxC enzyme from different species, including P. aeruginosa, [59,63,[65][66][67][68][69] Aquifex aeolicus, [67,[70][71][72][73][74][75] Yersinia enterocolitica [76] and E. coli, [52,77] have been solved, either as an apo-form or in complex mainly with inhibitors and these structures provide a good understanding at the molecular level of the differences in the inhibitory potency observed experimentally. The identification of these lead compounds was the result of the synthesis of a very large number of compounds in which mainly diverse moieties that mimic the fatty acid chain of the substrate were explored.…”